Please go to the PowerPak homepage
and select a course.
Diabetes Management with GLP-1 Receptor Agonists: Patient Perspectives and Pharmacist Insights (Webinar Archive)
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Novo Nordisk, Inc.
Jennifer Trujillo, PharmD, FCCP, BCPS, CDCES, BC-ADM
Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Clinical Pharmacist and Certified Diabetes Care and Education Specialist
UCHealth Diabetes and Endocrinology Clinic
Anschutz Medical Campus
Heather P. Whitley, PharmD, BCPS, CDCES
Clinical Professor of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Dr. Trujillo has disclosed that she has served as a consultant for Sanofi and Novo Nordisk, Inc.
Dr. Whitley has disclosed that she has served as a consultant for the Medication Information Institute.
The patients participating in this program have no relevant financial relationships to disclose.
The clinical reviewer, Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES has disclosed that she has received fees for consulting and non-CME services from Novo Nordisk, Inc.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education..
Credits: 1.5 hour (0.15 ceu)
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes
September 27, 2021
September 22, 2022
This accredited activity has been designed for pharmacists, all settings.
How to Earn Credit
During the period September 27, 2021 to September 22, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To educate pharmacists on the most up-to-date information on the use of GLP-1 Receptor Agonists (Ras) for Type 2 Diabetes (T2D) including the patient perspective. This includes in-depth discussions of new agents, review and application of current clinical practice recommendations, review of data on cardiovascular outcomes, and practical discussions regarding patient management. This educational initiative will provide learners with the knowledge and competence to improve the care and outcomes of patients with T2D.
Upon completion of this educational activity, participants should be better able to:
- Discuss current clinical practice recommendations concerning use of GLP-1 RAs in patients with T2D to improve glycemia and/or mitigate CV and kidney risk
- Assess patient-specific considerations when deciding between an agent from the GLP-1 RA or treatment options in a patient with T2D
- Apply an understanding of the patient experience with GLP-1 RAs to inform shared decision-making thus leading to optimized patient-centered care
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Novo Nordisk, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.